Rifampin Prophylaxis v Placebo for Household Contacts of Children With Hemophilus influenzae Type b Disease

T. V. Murphy, D. F. Chrane, G. H. McCracken, J. D. Nelson

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

The efficacy of rifampin prophylaxis (20 mg/kg/day in two doses for four days) in eliminating pharyngeal Hemophilus influenzae type b from household contacts of 38 patients with invasive Hemophilus disease was evaluated in a prospective, placebo-controlled fashion. At the end of treatment, rifampin efficacy was 91% in subjects younger than 5 years of age and 100% in those subjects older than 5 years. The H influenzae type b carrier rate of rifampin-treated subjects was significantly smaller than that of placebo-treated subjects one month after prophylaxis. However, 22% to 25% of rifampin-treated carriers younger than 5 years of age were colonized with H influenzae type b, based on cultures obtained one to four weeks after prophylaxis, while approximately 75% of placebo-treated carriers were still positive at this time.

Original languageEnglish (US)
Pages (from-to)627-632
Number of pages6
JournalAmerican Journal of Diseases of Children
Volume137
Issue number7
DOIs
StatePublished - Jul 1983

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Rifampin Prophylaxis v Placebo for Household Contacts of Children With Hemophilus influenzae Type b Disease'. Together they form a unique fingerprint.

Cite this